Financing ·
Shuttle Pharmaceuticals issues nearly 3.7M shares upon preferred stock conversion and sells warrants for approx 16.9M shares
SHPHShuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. issued 3,737,482 shares of common stock upon the conversion of Series B-1 and Series B-2 Preferred Stock as of September 14, 2026, subject to beneficial ownership limitations. Concurrently, the company issued warrants for approximately 927,114 shares at an exercise price of $10.30 per share and pre-funded warrants for approximately 16,932,508 shares following stockholder approval on September 9, 2026. These unregistered securities were issued in reliance on Section 4(a)(2) exemptions. Shuttle Pharmaceuticals Holdings, Inc. operates in the biopharmaceutical industry, focusing on drug discovery and development.